Treating Multiple Myeloma in Europe
Emerging and Practical Concepts in Multiple Myeloma
Overview
In recent years, progress in the understanding of multiple myeloma has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Multiple Myeloma Academy to help physicians who treat multiple myeloma bridge the gap between innovation and implementation of patient care.
Date and Location
18–19 March 2022, Virtual Meeting
Faculty
Rafael Fonseca, MD
Mayo Clinic Cancer Center, USA
Irene Ghobrial, MD
Dana-Farber Cancer Institute, USA
María-Victoria Mateos, MD, PhD
University of Salamanca, Spain
Keith Stewart, MBChB, MBA
Princess Margaret Cancer Centre, Canada
Bruno Paiva, PharmD, PhD
University of Navarra, Spain
Xavier Leleu, MD, PhD
Poitiers University Hospital, CHU, France
Meletios A. Dimopoulos, MD
National and Kapodistrian University of Athens School of Medicine, Greece
Hermann Einsele, MD, FRCP
University Hospital Würzburg, Germany
|
Agenda |
This virtual program was held over 2 days. |
Day 1: Friday, March 18, 2022
17.00 – 20.00 (CET) / 10.00 AM – 1.00 PM (MST)
| Time | Topic | Presenter |
| 17.00 – 17.10 10 min |
Welcome and Meeting Overview • Introduction to audience response system (ARS) |
Rafael Fonseca, MD |
| 17.10 – 17.30 20 min |
Smoldering Multiple Myeloma • Diagnosis, criteria, and when and how to intervene (15 min, 5-min discussion) |
Irene Ghobrial, MD |
| 17.30 – 17.50 20 min |
Importance of Minimal Residual Disease and Genetic Testing in Multiple Myeloma • Prognostic value, clinical relevance, and MRD-driven therapeutic guidance (15 min, 5-min discussion) |
Bruno Paiva, PharmD, PhD |
| 17.50 – 18.10 20 min |
Frontline Therapy for Newly Diagnosed Transplant-Eligible Multiple Myeloma: The Role of Transplantation • Guidelines, induction therapies, and when and how to transplant (15 min, 5-min discussion) |
María-Victoria Mateos, MD, PhD |
| 18.10 – 18.30 20 min |
Panel Discussion • Regional challenges of multiple myeloma diagnosis and treatment (2 × 10-min discussion) |
Bruno Paiva, PharmD, PhD Hermann Einsele, MD, FRCP All Faculty |
| 18.30 – 18.35 5 min |
Break | |
| 18.35 – 18.55 20 min |
Optimal Use of Consolidation and Maintenance Therapy • Evolving insights in consolidation and maintenance treatment after transplant (15 min, 5-min discussion) |
Xavier Leleu, MD, PhD |
| 18.55 – 19.20 25 min |
Frontline Therapy for Newly Diagnosed Transplant-Ineligible Patients • Criteria, guidelines, and treatment choices (15 min, 10-min discussion) |
Keith Stewart, MBChB, MBA |
| 19.20 – 19.50 30 min |
Debate • Smoldering myeloma: to treat or not to treat? • Is myeloma curable or not? (15 min + 15 min) |
Irene Ghobrial (yes) vs Meletios Dimopoulos (no); Rafael Fonseca (yes) vs Xavier Leleu (no) |
| 19.50 – 20.00 10 min |
Session Close • ARS questions |
Rafael Fonseca, MD |
Day 2: Saturday, March 19, 2022
17.00 – 20.00 (CET) / 10.00 AM – 1.00 PM (MST)
| Time (CET) | Topic | Presenter |
| 17.00 – 17.10 10 min |
Session Open | Rafael Fonseca, MD |
| 17.10 – 17.30 20 min |
Identification and Special Considerations for High-Risk Multiple Myeloma • Risk stratification, prognosis, and treatment choices (15 min, 5-min discussion) |
Meletios A. Dimopoulos, MD |
| 17.30 – 17.55 25 min |
Management of Early Relapse of Multiple Myeloma • Definition, prognosis, and treatment choices (15 min, 10-min discussion) |
Rafael Fonseca, MD |
| 17.55 – 18.20 25 min |
Management of Heavily Pretreated Multiple Myeloma • Optimal use of treatment choices in relapsed/refractory multiple myeloma (15 min, 10-min discussion) |
Keith Stewart, MBChB, MBA |
| 18.20 – 18.30 10 min |
Break | |
| 18.30 – 19.25 55 min |
Bispecifics in Multiple Myeloma and CAR Ts in Multiple Myeloma • Promising new developments in relapsed/refractory MM • Latest trial updates and upcoming new strategies; focus on BCMA-directed therapies (20 min + 20 min; 15-min discussion) |
María-Victoria Mateos, MD, PhD Hermann Einsele, MD, FRCP |
| 19.25 – 19.55 30 min |
Patient Case Discussion: Relapsed/Refractory Multiple Myeloma • Cases from the region will be discussed with the faculty – “tumor board approach” • Relapsed/refractory multiple myeloma, treatment challenges in the region • Case 1 Borja Puertas Martinez (Spain) department María-Victoria Mateos • Case 2 Despina Fotiou (Greece) department Meletios A. Dimopoulos (10–15 min per case including discussion) |
Regional case presenter All faculty |
| 19.55 – 20.00 5 min |
Session Close • ARS questions |
Rafael Fonseca, MD |
